Chester County News and Community Website
Immunome (NASDAQ: IMNM), headquartered in Exton, PA, is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information about the company, visit http://immunome.com.
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a Pennsylvania-based biopharmaceutical company, announced the recent appointment of Carol A. Schafer to its Board of Directors, marking another strategic move for the …
Immunome Appoints Experienced Investment Banker, Carol A. Schafer, to Board of Directors Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a leading biotech firm specializing in cancer therapies, recently announced its plan to purchase a trove of antibody-related assets from Atreca, Inc. (Nasdaq: …
Immunome Set to Acquire Atreca’s Antibody-Related Assets in a Move to Revolutionize Cancer Therapies Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced its third-quarter financial results ending September 30, 2023, and provided a corporate update that includes the completion of a significant merger …
Immunome Merges with Morphimmune, Secures $125M in Funding for Accelerated Cancer Therapy Development Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced the recent appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the …
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors Read More